Latest Breaking News On - Phase 3 lotis 5 trial - Page 1 : comparemela.com

Loncastuximab tesirine-lpyl plus rituximab demonstrated promising antitumor activity and consistent safety signals in patients with relapsed/refractory diffuse large B-cell lymphoma.

United statesMichal kwiatekMohamed zakiSociety of hematologic oncologyCentrum medyczne pratia poznanAnn arborHematologic oncologySociety of hematologic oncology annual meeting sohoNon hodgkin lymphomaRelapsed refractory diffuse largeb cell lymphomaPhase 3 lotis 5 trial